Fulgent Genetics Inc Stock News

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...

Second Quarter 2020 Results: * Record Revenue of $17.3 million, growing 105% year-over-year * Record Billable tests delivered total 180,513, growing 1003% year-over-year * Gross Margin improved a

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) ABIOMED, Inc. (NASDAQ: ABMD) ALX Oncology Holdings Inc (NASDAQ: ALXO) Annexon Inc (NASDAQ: ANNX) Atossa...

Fulgent Genetics (NASDAQ:FLGT) will issue its quarterly earnings data after the market closes on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.03) per share for the quar

Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in,...

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) Axonics Modulation Technologies Inc (NASDAQ: AXNX) Capricor Therapeutics Inc (NASDAQ: CAPR) Fulgent Genetics Inc...

Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO)...

Old West manages long only and long/short investment strategies based upon the companies that we uncover through our simple yet sound investment process.

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 23) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Acceleron Pharma Inc (NASDAQ: XLRN) Aerpio...

Fulgent Genetics (NASDAQ:FLGT) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a note issued to investors on Thursday, BidAskClub reports. Other analysts

TEMPLE CITY, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2020

Today, we take a look at Fulgent Generics, a fast growing and intriguing testing concern. The shares have bounced back nicely since their March lows, and the company is rapidly closing in on breakeven

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma